Pharvaris N.V.
Get $10 bonus on your first $100 deposit for PHVS
Get $10 bonus on your first $100 deposit for PHVS
Pharvaris N.V. (PHVS) Stock Competitors & Peer Comparison
See (PHVS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHVS | $29.14 | +1.60% | 1.9B | -8.42 | -$3.46 | N/A |
| VRTX | $441.70 | -0.58% | 112.2B | 28.85 | $15.31 | N/A |
| REGN | $753.93 | -0.21% | 78.3B | 18.17 | $41.49 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $840.87 | +1.51% | 52.1B | 42.92 | $19.60 | N/A |
| ALNY | $333.39 | -1.77% | 44.2B | 141.82 | $2.35 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $146.74 | -4.34% | 31.6B | -22.86 | -$6.42 | N/A |
| RVMD | $152.54 | +3.76% | 30.2B | -25.64 | -$5.95 | N/A |
| UTHR | $577.58 | -0.17% | 25.3B | 20.75 | $27.84 | N/A |
Stock Comparison
PHVS vs VRTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, VRTX has a market cap of 112.2B. Regarding current trading prices, PHVS is priced at $29.14, while VRTX trades at $441.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas VRTX's P/E ratio is 28.85. In terms of profitability, PHVS's ROE is -0.71%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PHVS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check VRTX's competition here
PHVS vs REGN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, PHVS is priced at $29.14, while REGN trades at $753.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas REGN's P/E ratio is 18.17. In terms of profitability, PHVS's ROE is -0.71%, compared to REGN's ROE of +0.15%. Regarding short-term risk, PHVS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check REGN's competition here
PHVS vs VRNA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PHVS is priced at $29.14, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PHVS's ROE is -0.71%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, PHVS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check VRNA's competition here
PHVS vs ARGX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ARGX has a market cap of 52.1B. Regarding current trading prices, PHVS is priced at $29.14, while ARGX trades at $840.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ARGX's P/E ratio is 42.92. In terms of profitability, PHVS's ROE is -0.71%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, PHVS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ARGX's competition here
PHVS vs ALNY Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ALNY has a market cap of 44.2B. Regarding current trading prices, PHVS is priced at $29.14, while ALNY trades at $333.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ALNY's P/E ratio is 141.82. In terms of profitability, PHVS's ROE is -0.71%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, PHVS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ALNY's competition here
PHVS vs SGEN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PHVS is priced at $29.14, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PHVS's ROE is -0.71%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PHVS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check SGEN's competition here
PHVS vs INSM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, INSM has a market cap of 31.6B. Regarding current trading prices, PHVS is priced at $29.14, while INSM trades at $146.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas INSM's P/E ratio is -22.86. In terms of profitability, PHVS's ROE is -0.71%, compared to INSM's ROE of -1.68%. Regarding short-term risk, PHVS is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check INSM's competition here
PHVS vs RVMD Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RVMD has a market cap of 30.2B. Regarding current trading prices, PHVS is priced at $29.14, while RVMD trades at $152.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RVMD's P/E ratio is -25.64. In terms of profitability, PHVS's ROE is -0.71%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, PHVS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check RVMD's competition here
PHVS vs UTHR Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, UTHR has a market cap of 25.3B. Regarding current trading prices, PHVS is priced at $29.14, while UTHR trades at $577.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas UTHR's P/E ratio is 20.75. In terms of profitability, PHVS's ROE is -0.71%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PHVS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check UTHR's competition here
PHVS vs BNTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BNTX has a market cap of 25B. Regarding current trading prices, PHVS is priced at $29.14, while BNTX trades at $99.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BNTX's P/E ratio is -18.15. In terms of profitability, PHVS's ROE is -0.71%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, PHVS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BNTX's competition here
PHVS vs MRNA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, PHVS is priced at $29.14, while MRNA trades at $54.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MRNA's P/E ratio is -7.47. In terms of profitability, PHVS's ROE is -0.71%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, PHVS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MRNA's competition here
PHVS vs ROIV Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, PHVS is priced at $29.14, while ROIV trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ROIV's P/E ratio is -25.12. In terms of profitability, PHVS's ROE is -0.71%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, PHVS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ROIV's competition here
PHVS vs RPRX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, PHVS is priced at $29.14, while RPRX trades at $48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RPRX's P/E ratio is 27.36. In terms of profitability, PHVS's ROE is -0.71%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, PHVS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RPRX's competition here
PHVS vs BGNE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PHVS is priced at $29.14, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PHVS's ROE is -0.71%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, PHVS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BGNE's competition here
PHVS vs INCY Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, PHVS is priced at $29.14, while INCY trades at $97.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas INCY's P/E ratio is 15.15. In terms of profitability, PHVS's ROE is -0.71%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PHVS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check INCY's competition here
PHVS vs DNA-WT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PHVS is priced at $29.14, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PHVS's ROE is -0.71%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, PHVS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check DNA-WT's competition here
PHVS vs GMAB Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, GMAB has a market cap of 18.1B. Regarding current trading prices, PHVS is priced at $29.14, while GMAB trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas GMAB's P/E ratio is 19.03. In terms of profitability, PHVS's ROE is -0.71%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PHVS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check GMAB's competition here
PHVS vs SMMT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, SMMT has a market cap of 15.7B. Regarding current trading prices, PHVS is priced at $29.14, while SMMT trades at $21.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas SMMT's P/E ratio is -14.67. In terms of profitability, PHVS's ROE is -0.71%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, PHVS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check SMMT's competition here
PHVS vs BBIO Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, PHVS is priced at $29.14, while BBIO trades at $77.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BBIO's P/E ratio is -20.56. In terms of profitability, PHVS's ROE is -0.71%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, PHVS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check BBIO's competition here
PHVS vs ASND Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, PHVS is priced at $29.14, while ASND trades at $241.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ASND's P/E ratio is -54.93. In terms of profitability, PHVS's ROE is -0.71%, compared to ASND's ROE of +1.28%. Regarding short-term risk, PHVS is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ASND's competition here
PHVS vs IONS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, PHVS is priced at $29.14, while IONS trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas IONS's P/E ratio is -32.28. In terms of profitability, PHVS's ROE is -0.71%, compared to IONS's ROE of -0.69%. Regarding short-term risk, PHVS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check IONS's competition here
PHVS vs KRTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PHVS is priced at $29.14, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PHVS's ROE is -0.71%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PHVS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KRTX's competition here
PHVS vs JAZZ Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, JAZZ has a market cap of 12.3B. Regarding current trading prices, PHVS is priced at $29.14, while JAZZ trades at $199.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas JAZZ's P/E ratio is -34.13. In terms of profitability, PHVS's ROE is -0.71%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, PHVS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check JAZZ's competition here
PHVS vs MDGL Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, PHVS is priced at $29.14, while MDGL trades at $518.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MDGL's P/E ratio is -40.36. In terms of profitability, PHVS's ROE is -0.71%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, PHVS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MDGL's competition here
PHVS vs EXEL Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, PHVS is priced at $29.14, while EXEL trades at $44.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas EXEL's P/E ratio is 15.93. In terms of profitability, PHVS's ROE is -0.71%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, PHVS is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check EXEL's competition here
PHVS vs RNAM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PHVS is priced at $29.14, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PHVS's ROE is -0.71%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PHVS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RNAM's competition here
PHVS vs BMRN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, PHVS is priced at $29.14, while BMRN trades at $55.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BMRN's P/E ratio is 30.71. In terms of profitability, PHVS's ROE is -0.71%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, PHVS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BMRN's competition here
PHVS vs ARWR Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ARWR has a market cap of 9.9B. Regarding current trading prices, PHVS is priced at $29.14, while ARWR trades at $70.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ARWR's P/E ratio is 44.34. In terms of profitability, PHVS's ROE is -0.71%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, PHVS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ARWR's competition here
PHVS vs RXDX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PHVS is priced at $29.14, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PHVS's ROE is -0.71%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PHVS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RXDX's competition here
PHVS vs AXSM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, PHVS is priced at $29.14, while AXSM trades at $184.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas AXSM's P/E ratio is -49.91. In terms of profitability, PHVS's ROE is -0.71%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, PHVS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check AXSM's competition here
PHVS vs TECH Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, PHVS is priced at $29.14, while TECH trades at $58.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas TECH's P/E ratio is 110.36. In terms of profitability, PHVS's ROE is -0.71%, compared to TECH's ROE of +0.04%. Regarding short-term risk, PHVS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TECH's competition here
PHVS vs IMGN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PHVS is priced at $29.14, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PHVS's ROE is -0.71%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PHVS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check IMGN's competition here
PHVS vs PCVX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, PCVX has a market cap of 8.7B. Regarding current trading prices, PHVS is priced at $29.14, while PCVX trades at $60.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas PCVX's P/E ratio is -10.74. In terms of profitability, PHVS's ROE is -0.71%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, PHVS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PCVX's competition here
PHVS vs BPMC Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PHVS is priced at $29.14, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PHVS's ROE is -0.71%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, PHVS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BPMC's competition here
PHVS vs CERE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PHVS is priced at $29.14, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, PHVS's ROE is -0.71%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PHVS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CERE's competition here
PHVS vs HALO Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, PHVS is priced at $29.14, while HALO trades at $68.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas HALO's P/E ratio is 26.58. In terms of profitability, PHVS's ROE is -0.71%, compared to HALO's ROE of +0.93%. Regarding short-term risk, PHVS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check HALO's competition here
PHVS vs CYTK Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, PHVS is priced at $29.14, while CYTK trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CYTK's P/E ratio is -10.00. In terms of profitability, PHVS's ROE is -0.71%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, PHVS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CYTK's competition here
PHVS vs IBRX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, IBRX has a market cap of 8B. Regarding current trading prices, PHVS is priced at $29.14, while IBRX trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas IBRX's P/E ratio is -20.47. In terms of profitability, PHVS's ROE is -0.71%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, PHVS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check IBRX's competition here
PHVS vs ABVX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, PHVS is priced at $29.14, while ABVX trades at $121.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ABVX's P/E ratio is -21.55. In terms of profitability, PHVS's ROE is -0.71%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, PHVS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ABVX's competition here
PHVS vs KRYS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, PHVS is priced at $29.14, while KRYS trades at $268.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas KRYS's P/E ratio is 39.26. In terms of profitability, PHVS's ROE is -0.71%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PHVS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KRYS's competition here
PHVS vs NUVL Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, PHVS is priced at $29.14, while NUVL trades at $104.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas NUVL's P/E ratio is -17.91. In terms of profitability, PHVS's ROE is -0.71%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, PHVS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check NUVL's competition here
PHVS vs MTSR Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PHVS is priced at $29.14, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PHVS's ROE is -0.71%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, PHVS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MTSR's competition here
PHVS vs KYMR Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, PHVS is priced at $29.14, while KYMR trades at $89.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas KYMR's P/E ratio is -24.12. In terms of profitability, PHVS's ROE is -0.71%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, PHVS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KYMR's competition here
PHVS vs PRAX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, PHVS is priced at $29.14, while PRAX trades at $339.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas PRAX's P/E ratio is -25.22. In terms of profitability, PHVS's ROE is -0.71%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, PHVS is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PRAX's competition here
PHVS vs MRUS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PHVS is priced at $29.14, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PHVS's ROE is -0.71%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, PHVS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MRUS's competition here
PHVS vs BLTE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $29.14, while BLTE trades at $168.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BLTE's P/E ratio is -73.06. In terms of profitability, PHVS's ROE is -0.71%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, PHVS is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BLTE's competition here
PHVS vs PTGX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $29.14, while PTGX trades at $105.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas PTGX's P/E ratio is -51.43. In terms of profitability, PHVS's ROE is -0.71%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, PHVS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PTGX's competition here
PHVS vs ACLX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $29.14, while ACLX trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ACLX's P/E ratio is -28.25. In terms of profitability, PHVS's ROE is -0.71%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PHVS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ACLX's competition here
PHVS vs RETA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PHVS is priced at $29.14, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, PHVS's ROE is -0.71%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PHVS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RETA's competition here
PHVS vs PTCT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, PHVS is priced at $29.14, while PTCT trades at $73.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas PTCT's P/E ratio is 8.57. In terms of profitability, PHVS's ROE is -0.71%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, PHVS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check PTCT's competition here
PHVS vs RYTM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, PHVS is priced at $29.14, while RYTM trades at $87.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RYTM's P/E ratio is -28.23. In terms of profitability, PHVS's ROE is -0.71%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, PHVS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check RYTM's competition here
PHVS vs CELC Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, PHVS is priced at $29.14, while CELC trades at $123.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CELC's P/E ratio is -32.49. In terms of profitability, PHVS's ROE is -0.71%, compared to CELC's ROE of -2.03%. Regarding short-term risk, PHVS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CELC's competition here
PHVS vs CAI Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CAI has a market cap of 5.9B. Regarding current trading prices, PHVS is priced at $29.14, while CAI trades at $20.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CAI's P/E ratio is -6.51. In terms of profitability, PHVS's ROE is -0.71%, compared to CAI's ROE of +0.25%. Regarding short-term risk, PHVS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CAI's competition here
PHVS vs CNTA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, PHVS is priced at $29.14, while CNTA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CNTA's P/E ratio is -27.13. In terms of profitability, PHVS's ROE is -0.71%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, PHVS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CNTA's competition here
PHVS vs COGT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, PHVS is priced at $29.14, while COGT trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas COGT's P/E ratio is -16.81. In terms of profitability, PHVS's ROE is -0.71%, compared to COGT's ROE of -1.00%. Regarding short-term risk, PHVS is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check COGT's competition here
PHVS vs CGON Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, PHVS is priced at $29.14, while CGON trades at $67.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CGON's P/E ratio is -32.54. In terms of profitability, PHVS's ROE is -0.71%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PHVS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CGON's competition here
PHVS vs SRRK Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, PHVS is priced at $29.14, while SRRK trades at $49.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas SRRK's P/E ratio is -14.99. In terms of profitability, PHVS's ROE is -0.71%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, PHVS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check SRRK's competition here
PHVS vs ERAS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, PHVS is priced at $29.14, while ERAS trades at $18.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ERAS's P/E ratio is -41.36. In terms of profitability, PHVS's ROE is -0.71%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, PHVS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ERAS's competition here
PHVS vs CDTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PHVS is priced at $29.14, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PHVS's ROE is -0.71%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, PHVS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CDTX's competition here
PHVS vs IMVT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, PHVS is priced at $29.14, while IMVT trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas IMVT's P/E ratio is -10.27. In terms of profitability, PHVS's ROE is -0.71%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, PHVS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check IMVT's competition here
PHVS vs ALKS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ALKS has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $29.14, while ALKS trades at $33.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ALKS's P/E ratio is 23.22. In terms of profitability, PHVS's ROE is -0.71%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, PHVS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ALKS's competition here
PHVS vs TGTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $29.14, while TGTX trades at $34.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas TGTX's P/E ratio is 12.49. In terms of profitability, PHVS's ROE is -0.71%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, PHVS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TGTX's competition here
PHVS vs ABCM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $29.14, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PHVS's ROE is -0.71%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PHVS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ABCM's competition here
PHVS vs ISEE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $29.14, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PHVS's ROE is -0.71%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PHVS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ISEE's competition here
PHVS vs CRSP Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, PHVS is priced at $29.14, while CRSP trades at $56.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CRSP's P/E ratio is -8.77. In terms of profitability, PHVS's ROE is -0.71%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, PHVS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CRSP's competition here
PHVS vs FBIOX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, PHVS is priced at $29.14, while FBIOX trades at $25.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas FBIOX's P/E ratio is N/A. In terms of profitability, PHVS's ROE is -0.71%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, PHVS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check FBIOX's competition here
PHVS vs APLS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, PHVS is priced at $29.14, while APLS trades at $40.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas APLS's P/E ratio is 226.92. In terms of profitability, PHVS's ROE is -0.71%, compared to APLS's ROE of +0.08%. Regarding short-term risk, PHVS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check APLS's competition here
PHVS vs APGE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, APGE has a market cap of 5B. Regarding current trading prices, PHVS is priced at $29.14, while APGE trades at $89.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas APGE's P/E ratio is -21.17. In terms of profitability, PHVS's ROE is -0.71%, compared to APGE's ROE of -0.37%. Regarding short-term risk, PHVS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check APGE's competition here
PHVS vs MIRM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, PHVS is priced at $29.14, while MIRM trades at $96.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MIRM's P/E ratio is -205.11. In terms of profitability, PHVS's ROE is -0.71%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, PHVS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MIRM's competition here
PHVS vs TERN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, PHVS is priced at $29.14, while TERN trades at $52.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas TERN's P/E ratio is -51.17. In terms of profitability, PHVS's ROE is -0.71%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PHVS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TERN's competition here
PHVS vs CORT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CORT has a market cap of 4.7B. Regarding current trading prices, PHVS is priced at $29.14, while CORT trades at $43.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CORT's P/E ratio is 53.54. In terms of profitability, PHVS's ROE is -0.71%, compared to CORT's ROE of +0.15%. Regarding short-term risk, PHVS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CORT's competition here
PHVS vs XENE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, PHVS is priced at $29.14, while XENE trades at $58.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas XENE's P/E ratio is -13.50. In terms of profitability, PHVS's ROE is -0.71%, compared to XENE's ROE of -0.56%. Regarding short-term risk, PHVS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check XENE's competition here
PHVS vs FOLD Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $29.14, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas FOLD's P/E ratio is -160.67. In terms of profitability, PHVS's ROE is -0.71%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PHVS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check FOLD's competition here
PHVS vs AKRO Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $29.14, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PHVS's ROE is -0.71%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, PHVS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check AKRO's competition here
PHVS vs LGND Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $29.14, while LGND trades at $225.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas LGND's P/E ratio is 36.72. In terms of profitability, PHVS's ROE is -0.71%, compared to LGND's ROE of +0.14%. Regarding short-term risk, PHVS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check LGND's competition here
PHVS vs ALPN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $29.14, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PHVS's ROE is -0.71%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PHVS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ALPN's competition here
PHVS vs OPT Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PHVS is priced at $29.14, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, PHVS's ROE is -0.71%, compared to OPT's ROE of +0.88%. Regarding short-term risk, PHVS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check OPT's competition here
PHVS vs SYRE Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, PHVS is priced at $29.14, while SYRE trades at $68.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas SYRE's P/E ratio is -34.84. In terms of profitability, PHVS's ROE is -0.71%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, PHVS is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check SYRE's competition here
PHVS vs CRNX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, PHVS is priced at $29.14, while CRNX trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CRNX's P/E ratio is -8.03. In terms of profitability, PHVS's ROE is -0.71%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, PHVS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CRNX's competition here
PHVS vs MRTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PHVS is priced at $29.14, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PHVS's ROE is -0.71%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PHVS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MRTX's competition here
PHVS vs VKTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, PHVS is priced at $29.14, while VKTX trades at $35.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas VKTX's P/E ratio is -11.11. In terms of profitability, PHVS's ROE is -0.71%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, PHVS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check VKTX's competition here
PHVS vs NAMS Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, PHVS is priced at $29.14, while NAMS trades at $34.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas NAMS's P/E ratio is -19.77. In terms of profitability, PHVS's ROE is -0.71%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, PHVS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check NAMS's competition here
PHVS vs LEGN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $29.14, while LEGN trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas LEGN's P/E ratio is -12.67. In terms of profitability, PHVS's ROE is -0.71%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, PHVS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check LEGN's competition here
PHVS vs TVTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, TVTX has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $29.14, while TVTX trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas TVTX's P/E ratio is -71.84. In terms of profitability, PHVS's ROE is -0.71%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, PHVS is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check TVTX's competition here
PHVS vs RYZB Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $29.14, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PHVS's ROE is -0.71%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PHVS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RYZB's competition here
PHVS vs CBAY Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $29.14, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PHVS's ROE is -0.71%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PHVS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CBAY's competition here
PHVS vs ACAD Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $29.14, while ACAD trades at $21.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas ACAD's P/E ratio is 9.46. In terms of profitability, PHVS's ROE is -0.71%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, PHVS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ACAD's competition here
PHVS vs DNTH Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $29.14, while DNTH trades at $95.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas DNTH's P/E ratio is -22.80. In terms of profitability, PHVS's ROE is -0.71%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, PHVS is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check DNTH's competition here
PHVS vs EWTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, PHVS is priced at $29.14, while EWTX trades at $33.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas EWTX's P/E ratio is -20.67. In terms of profitability, PHVS's ROE is -0.71%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, PHVS is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check EWTX's competition here
PHVS vs TLX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, PHVS is priced at $29.14, while TLX trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas TLX's P/E ratio is -533.00. In terms of profitability, PHVS's ROE is -0.71%, compared to TLX's ROE of -0.02%. Regarding short-term risk, PHVS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TLX's competition here
PHVS vs SWTX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PHVS is priced at $29.14, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PHVS's ROE is -0.71%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, PHVS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check SWTX's competition here
PHVS vs LQDA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, LQDA has a market cap of 3.5B. Regarding current trading prices, PHVS is priced at $29.14, while LQDA trades at $40.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas LQDA's P/E ratio is -50.15. In terms of profitability, PHVS's ROE is -0.71%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, PHVS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check LQDA's competition here
PHVS vs DNLI Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, PHVS is priced at $29.14, while DNLI trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas DNLI's P/E ratio is -7.30. In terms of profitability, PHVS's ROE is -0.71%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, PHVS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check DNLI's competition here
PHVS vs KNSA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, PHVS is priced at $29.14, while KNSA trades at $45.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas KNSA's P/E ratio is 61.19. In terms of profitability, PHVS's ROE is -0.71%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, PHVS is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check KNSA's competition here
PHVS vs DYN Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, DYN has a market cap of 3.3B. Regarding current trading prices, PHVS is priced at $29.14, while DYN trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas DYN's P/E ratio is -5.76. In terms of profitability, PHVS's ROE is -0.71%, compared to DYN's ROE of -0.61%. Regarding short-term risk, PHVS is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check DYN's competition here
PHVS vs CPRX Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, PHVS is priced at $29.14, while CPRX trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas CPRX's P/E ratio is 15.39. In terms of profitability, PHVS's ROE is -0.71%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PHVS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CPRX's competition here
PHVS vs BEAM Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, PHVS is priced at $29.14, while BEAM trades at $30.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas BEAM's P/E ratio is -37.88. In terms of profitability, PHVS's ROE is -0.71%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, PHVS is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check BEAM's competition here
PHVS vs GPCR Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, PHVS is priced at $29.14, while GPCR trades at $54.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas GPCR's P/E ratio is -22.60. In terms of profitability, PHVS's ROE is -0.71%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, PHVS is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check GPCR's competition here
PHVS vs VERA Comparison April 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 1.9B. In comparison, VERA has a market cap of 3.1B. Regarding current trading prices, PHVS is priced at $29.14, while VERA trades at $43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -8.42, whereas VERA's P/E ratio is -9.32. In terms of profitability, PHVS's ROE is -0.71%, compared to VERA's ROE of -0.60%. Regarding short-term risk, PHVS is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check VERA's competition here